Item 7.01 Regulation FD Disclosure.
On
June 9, 2021, Roivant Sciences Ltd. (“Roivant”) announced that Datavant Holdings, Inc. (“Datavant”) and CIOX
Health, LLC have signed a definitive merger agreement.
The
information in this Item 7.01 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed
to be incorporated by reference into the filings of Montes Archimedes Acquisition Corp. (“MAAC”) under the Securities Act
of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report will not
be deemed an admission as to the materiality of any information of the information in this Item 7.01.
Additional Information
In
connection with the previously announced proposed business combination between MAAC and Roivant (the “proposed business combination”),
Roivant has filed a Registration Statement on Form S-4 (the “Registration Statement”) with the SEC that includes a prospectus
with respect to Roivant’s securities to be issued in connection with the proposed business combination and a proxy statement with
respect to the stockholder meeting of MAAC to vote on the proposed business combination. Stockholders of MAAC and other interested
persons are encouraged to read the preliminary proxy statement/prospectus, as well as the annexes thereto and the other documents to be
filed with the SEC because these documents contain important information about MAAC, Roivant and the proposed business combination. After
the Registration Statement is declared effective, the definitive proxy statement/prospectus will be mailed to stockholders of MAAC as
of a record date to be established for voting on the proposed business combination. Stockholders of MAAC may also obtain a copy
of the Registration Statement, including the proxy statement/prospectus, and other documents filed or to be filed with the SEC without
charge, by directing a request to: Montes Archimedes Acquisition Corp., 724 Oak Grove Ave., Suite 130, Menlo Park, California 94025. The
proxy statement/prospectus to be included in the Registration Statement can also be obtained, without charge, at the SEC’s website
(www.sec.gov).
Participants in the Solicitation
MAAC,
Roivant, their affiliates, and their respective directors and executive officers may be considered participants in the solicitation
of proxies with respect to the proposed business combination described in this communication under the rules of the
SEC. Information about the directors and executive officers of MAAC and their ownership is set forth in MAAC’s
filings with the SEC, including its Form 10-K for the year ended December 31, 2020 (as amended on May 14, 2021) and subsequent
filings, including on Form 10-Q and Form 4, all of which are or will be available free of charge at the SEC’s website
at www.sec.gov or by directing a request to: Montes Archimedes Acquisition Corp., 724 Oak Grove Ave., Suite 130, Menlo
Park, California 94025. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in
the solicitation of the MAAC stockholders in connection with the proposed business combination is set forth in the Registration
Statement containing the preliminary proxy statement/prospectus filed with the SEC. These documents can be obtained free of charge
from the sources indicated above.
Forward Looking Statements
This
communication contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking
statements by the following words: “may,” “will,” “could,” “would,”
“should,” “expect,” “intend,” “plan,” “anticipate,”
“believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “ongoing,” “target,” “seek” or the negative or
plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking
statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or
circumstances, including strategies or plans as they relate to the proposed business combination, are also forward-looking statements.
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements
to be materially different from the information expressed or implied by these forward-looking statements. Although each of MAAC and Roivant
believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of MAAC and Roivant caution
you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently
uncertain. In addition, risks and uncertainties are described in the Registration Statement relating to the proposed business combination
filed by Roivant with the SEC and other documents filed by MAAC or Roivant from time to time with the SEC. These filings may identify
and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements in this communication include, but are not limited to, statements regarding
the proposed business combination, including the timing and structure of the transaction, the proceeds of the transaction and the benefits
of the transaction. Neither MAAC nor Roivant can assure you that the forward-looking statements in this communication will prove to be
accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to
complete the proposed business combination due to the failure to obtain approval from MAAC’s stockholders or satisfy other closing
conditions in the Business Combination Agreement entered into in connection with the proposed business combination (the “Business
Combination Agreement”), the occurrence of any event that could give rise to the termination of the Business Combination Agreement,
the ability to recognize the anticipated benefits of the proposed business combination, the amount of redemption requests made by MAAC’s
public stockholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts
current plans and operations as a result of the announcement and consummation of the proposed business combination, the outcome of any
potential litigation, government or regulatory proceedings and other risks and uncertainties, including those included under the heading
“Risk Factors” in the Registration Statement filed by Roivant with the SEC and those included under the heading “Risk
Factors” in MAAC’s annual report on Form 10-K for year ended December 31, 2020 (as amended on May 14, 2021) and in its subsequent
quarterly reports on Form 10-Q and other filings with the SEC. In light of the significant uncertainties in these forward-looking statements,
you should not regard these statements as a representation or warranty by MAAC, Roivant, their respective directors, officers or employees
or any other person that MAAC and Roivant will achieve their objectives and plans in any specified time frame, or at all. The forward-looking
statements in this communication represent the views of MAAC and Roivant, as applicable, as of the date of this communication. Subsequent
events and developments may cause that view to change. However, while MAAC and Roivant may elect to update these forward-looking statements
at some point in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore,
not rely on these forward-looking statements as representing the views of MAAC or Roivant as of any date subsequent to the date of this
communication.